Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Asthma Severity in Women: The Influence of Training and Menopause (ATOM)

17. června 2021 aktualizováno: Vibeke Backer, Rigshospitalet, Denmark

The ATOM Study: Asthma Severity in Women: The Influence of Training and Menopause

Introduction: Late-onset asthma in women is characterized by poor disease control and reduced quality of life despite intensive treatment with inhaled steroid and beta2-agonist. The condition is further worsened at menopause due to the loss of estrogen leading to increased asthma exacerbation frequency, increased airway inflammation and decreased lung function. Exercise training may increase disease control of asthma patients, but to what extent the same effect is seen in postmenopausal women with late-onset asthma is unknown. These asthma patients represent a phenotype that is characterized by low eosinophilic airway inflammation, severe symptoms, moderate obesity and poor response to conventional medicine. Thus, our hypothesis is that regular physical exercise is especially associated with an improvement in asthma control in this phenotype. The aim of this project is to test this hypothesis and to assess whether an improvement is associated with reduced local and systemic inflammation, change in heart function, lung function and/or body composition.

Study design: 40 postmenopausal women with late-onset asthma are recruited via the outpatient clinic at the Respiratory Department at Bispebjerg Hospital and through advertisement. The participants are randomized 1:1 into two groups. One group performs supervised exercise training (spinning) three times per week for 12 weeks while the other group is a control group. Before and after the intervention asthma control, local and systemic inflammation, heart function and body composition is measured.

Results: Analysis will be performed to detect changes within and between the groups before and after intervention. Primary outcome is change in ACQ (Asthma Control Questionnaire). Local and systemic inflammation is measured by changes in bronchial challenge to methacholine, sputum cell count and blood tests. Furthermore, secondary outcomes include change in heart function measured by stress-echocardiography and change in body composition measured by Dual-energy X-ray absorptiometry (DEXA).

Conclusion: There are to date no prospective studies that can support recommendations containing asthma rehabilitation with supervised regular physical activity for postmenopausal women. Thus, this study will provide novel understanding of the importance of physical activity in a chronic disease such as asthma.

Přehled studie

Postavení

Ukončeno

Detailní popis

Overall study design

The study is a single-blinded randomized controlled intervention study. Forty postmenopausal women with late-onset asthma (>16 years at debut) are recruited from the asthma outpatient-clinic at Bispebjerg Hospital or other hospital/practitioner in the region and/or by advertisement. The participants are block-randomized into two groups of 20, where one group is control and the other undergoes a period of regular exercise training. The investigators will be blinded and will not know whether the subjects have trained or not.

Detailed study design

Participants allocated to the exercise training group undergo a training intervention consisting of 45 minutes of intermittent high intensity aerobic spinning training three times per week for 12 weeks. Participants allocated to the control group will continue usual care without training. No changes to current treatment will be made by the investigators on any of the groups.

The training will consist of short periods of high intensity intervals where subjects reach above 80% of maximal oxygen consumption. Spinning sessions will be fully supervised by trained instructors with a bachelor of sports and science or bachelor of medicine and conducted in the Department of Nutrition, Exercise and Sports, University of Copenhagen. Subjects will wear heart rate monitors to ensure adherence to the training protocol. Within two weeks, before and after the intervention, participants from both groups undergo 3 days of testing.

To ensure equal compliance with asthma medication both groups will receive daily electronic reminders. Once a week, all participants will be asked about their compliance to their medication.

Typ studie

Intervenční

Zápis (Aktuální)

12

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Copenhagen, Dánsko, 2400
        • Respiratory research unit, Bispebjerg University Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

45 let až 75 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Late onset asthma (Debut ≥ 16 years of age)
  • ACQ ≥ 1.25
  • Daily treatment for asthma (GINA 2 and above)
  • Age 45 - 75
  • Postmenopausal defined as no menstruation for 6 months, Serum Follicle stimulating hormone >20 International Units per Liter and P-Estradiol nmol/L <0.09
  • BMI 25 - 35
  • Positive bronchial challenge to methacholine, mannitol or positive reversibility to beta2-agonist now or historically
  • Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 months)
  • Capable of exercising on a bike

Exclusion Criteria:

  • Unable to speak and understand Danish or English.
  • Current or former smokers (>6 months cessation) with >20 years of daily smoking with 20 cigarettes per day.
  • Other respiratory disease of clinical significance
  • Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (EF <40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (>155/100)
  • Any disorder that is not stable and in the opinion of the investigator could affect the safety of the subject throughout the study
  • Subjects, who by investigators determination, will not be able to adhere to study protocol

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Aerobic exercise intervention
Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
High Intensity Interval Training (HIIT)
Žádný zásah: Control group
No intervention for 12 weeks

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Asthma control - Asthma Control Questionnaire (ACQ)
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in Asthma Control Questionnaire (ACQ) 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use)
-21 to 0 days before intervention and 0 to 14 days post intervention

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Heart Rate Variability
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rate variability

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart rhytm
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rhythm

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart Rate
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- electrocardiography

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Strain
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Strain

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Ejection fraction
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Ejection fraction

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Tricuspid annular plane systolic excursion
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Tricuspid annular plane systolic excursion

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Right ventricular function
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Right ventricular function

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Pulmonary pressure
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Pulmonary pressure

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Lung covered cor
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Lung covered cor

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Blood pressure
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention
Blood pressure
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Cardiac output
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention
Cardiac output
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Stroke volume
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention
Stroke volume
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Total peripheral resistance
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention
Total peripheral resistance
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Leukocytes + differential cell count count
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Leukocytes + differential cell count count

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 6
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 6

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 8
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 8

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Other interleukins

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Tumor Necrosis Factor alpha
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Tumor Necrosis Factor alpha

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Total immunoglobulin E, Specific immunoglobulin E
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

  • Total immunoglobulin E
  • Specific immunoglobulin E
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - high sensitivity c reactive protein
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- high sensitivity c reactive protein

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Sputum cell count
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Sputum cell count

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Fraction of exhaled nitric oxide
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Fraction of exhaled nitric oxide

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Hyperreactivity to inhaled methacholine
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hyperreactivity to inhaled methacholine

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Total body fat

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Lean body mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Muscle mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Weight

-21 to 0 days before intervention and 0 to 14 days post intervention
Microbiome
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in the microbiota in sputum, oral cavity and nasal cavity before and after the training intervention
-21 to 0 days before intervention and 0 to 14 days post intervention
Compliance - Foster score
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Change in

- Foster score Answers describe last weeks medicine use. Answers range form 0/7 - 7/7 with low values being worse.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Nijmegen questionnaire
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Nijmegen questionnaire Values range from 0-64 and values below 20 are considered normal.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Mini Asthma Quality of Life Questionnaire (miniAQLQ)
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Mini Asthma Quality of Life Questionnaire (miniAQLQ) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired).

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Hospital Anxiety and Depression Scale (HADS) 2 items with 7 questions regarding anxiety and depression. (0 = no sign of depression/anxiety, 21 = maximal signs of anxiety/depression)
Časové okno: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hospital Anxiety and Depression Scale (HADS)

-21 to 0 days before intervention and 0 to 14 days post intervention

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Vibeke Backer, Physician, Respiratory Research Unit, Bispebjerg Hospital

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

12. února 2019

Primární dokončení (Aktuální)

1. května 2021

Dokončení studie (Aktuální)

1. května 2021

Termíny zápisu do studia

První předloženo

9. listopadu 2018

První předloženo, které splnilo kritéria kontroly kvality

19. listopadu 2018

První zveřejněno (Aktuální)

20. listopadu 2018

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

23. června 2021

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. června 2021

Naposledy ověřeno

1. června 2021

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Data that support the results of this study will be made available immediately, with no end date, after deidentification and upon reasonable request.

Časový rámec sdílení IPD

Immediately after publication with no end date.

Kritéria přístupu pro sdílení IPD

Data will be made available upon reasonable request to achieve the aims of the reasonable request.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit